I've read a lot of articles in the last few months saying that MCC has no treatments, no trials, and no upcoming studies on agents to treat the disease. ImmunoPulse is the only product being tested to treat this life-threatening disease, which makes me think that ONCS has a really good shot at earning a fast-track and potentially breakthrough indication.
OncoSec is being very active right now. The company is presenting for potential investors, expanding the use of ImmunoPulse, and is preparing data. Personally, I am more confident than ever before that ImmunoPulse will succeed. I don't think Roche would've partnered with INO or Pfizer with Ichor if electroporation did not work. ONCS is the best remaining company with the only programs in treating melanoma and MCC using electroporation. Due to the fact that Roche and Pfizer are now involved in this space, I think others like BMY, MRK, and AZN could be looking to partner.
I guess my question is that if Roche and Pfizer think electroporation works and is worth investing in, and if no other company is doing what ONCS is doing in connection with MCC, why didn't Roche and Pfizer partner with ONCS? Or did ONCS turn them down and we just don't know? While some might say "ONCS is waiting for great results so that they are worth more," I say that eventually, you can run out of big pharma suitors by waiting for the last nickel, plus, what did those other companies have that ONCS doesn't, if in fact they did not approach ONCS? Does anyone really know who Ichor is? Isn't MRK out the running now too? Maybe I heard wrong on that. Either way, I am long on ONCS and have faith that they know what they are doing. I am just curious as to why it seems there isn't the interest in them that there seems to have been on those other companies.